Acute Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects

Inclusion Criteria: * Presenting at least two of the following risks of suboptimal endothelial function (but not under prescribed drug for this reason): * Overweight, defined by: 25 ≤ BMI \< 30 kg/m2; * Central obesity defined according to IDE criteria (2009): for European subjects, waist circumference ≥ 94 cm (with a tolerance of -10%); * High Normal Blood pressure defined according to ESC/ESH guidelines (2013): Systolic Blood Pressure ≥ 130 and ≤ 139 mmHg or Diastolic Blood Pressure ≥ 85 and ≤ 89 mmHg; * Considered healthy based on their self-declaration and physical examination; * Subjects capable of and willing to comply with the protocol and to give their written informed consent. * Subjects affiliated with a social security scheme. Non-inclusion Criteria: * Metabolic abnormality or major cardiovascular risk factor, such as (but not limited to): * clinically significant arrhythmia, * diabetes mellitus (type I or II), * chronic kidney disease. * Consumption of food supplement(s) currently or within the past 4 weeks before entry into the study, such as but not limited to: botanicals, vitamins, minerals, amino acids; * Smoking \> 5 cigarettes/ day and \> 5 pack-years for at least 2 years; * Use of any type of medication currently or within 2 months before entry into the study (more especially antihypertensive drug); * Use of any narcotic drug (including cannabis) within 2 months before entry into the study detected by the self-declaration of the participant and/ or by the urine THC test ; * Endurance sport activities \> 5 h/ week; * Self-reported alcohol intake \>10 units/ week (1 unit = 1 standard glass) * Weight change \> 5% of total body weight within the 3 months before V1; * Currently under prescribed diet regimen, whatever the reason; * Any intolerance or allergy documented or suspected to one of the components of the study products or to the Glyceryl trinitrate (GTN); * Any contraindication to the GTN drug: * severe hypotension, * obstructive cardiomyopathy, * myocardial infarction, * intracranial hypertension, * sildenafil intake (occasionally or regularly). . * Subject presenting a psychological or linguistic inability to sign the informed consent; * Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision; * Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study; * Any regulatory reason according to national applicable regulation. Exclusion criteria : Volunteers whose fasting blood sample at V0 will reveal a pathological level of glycaemia (\> 1,26 g/L) and/ or a dyslipidemia (example : triacylglycerol \> 1,75 g/L) will be excluded.